Applied Clinical Trials | August 16, 2023

This atricle covers Pfizer ending their relationship with decentralized clinical trial (DCT) specialist CareAccess and how companies work together on GCP adherence. Our Senior GMP Quality Expert, Jerry Chapman gave his insights on the matter. Read the full article here.

Report – Expert Analysis: 22 years of FDA Drug GMP 483s

Webinar – Insights from Mapping API Inspection Deficiencies to the Quality Systems

Webinar – Legal Considerations | Interacting with the FDA Before, During, and After Inspections

Webinar – Quality Intelligence: from Information to Knowledge

Report – Analysis of FDA 483s Issued to Excipient Manufacturers Since 2000

Webinar – Comparing Inspection Observations between FDA and Health Canada

Report – Analysis of FDA Drug GMP Warning Letters for FY2022

Report – Breaking News: The First FDA Warning Letter to an Excipient Manufacturer

Report – Insights on Quality from FDA Leaders
« Older Entries
Newer Entries »